Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Tregs expansion can help prevent graft-versus-host disease

Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, researchers at Moffitt Cancer Center have tested a process by which T regulatory cells (Tregs) can be "expanded" to help prevent GVHD.

1 Nov 2011

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011

Dysregulated neuronal RNA transport may cause Fragile X-associated tremor/ataxia syndrome

SUNY Downstate scientist Ilham Muslimov, MD, PhD, along with senior author Henri Tiedge, PhD, professor of physiology and pharmacology and of neurology, published a study suggesting that cellular dysregulation associated with certain neurodegenerative disorders may result from molecular competition in neuronal RNA transport pathways.

8 Sep 2011

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

7 Sep 2011

Dendritic cells play central role in regulation of acetaminophen's toxicity

NYU School of Medicine researchers have discovered that dendritic cells in the liver have a protective role against the toxicity of acetaminophen, the widely used over-the-counter pain reliever and fever reducer for adults and children.

2 Sep 2011

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer.

4 Aug 2011

New details about how dendritic cells regulate fate of naive T cells

St. Jude Children's Research Hospital scientists show that the molecule serves as a bridge between the two arms of the immune system that provides a new mechanism guiding T cell differentiation.

25 Jul 2011

Renowned neurosurgeon to receive National Urban League's highest honor on July 30

Renowned neurosurgeon Keith L. Black, MD, will receive the National Urban League's highest honor on July 30 during the organization's annual conference in Boston.

22 Jul 2011

Skin dendritic cells promote distinct and opposing antigen-specific responses

A new study reveals that just as different soldiers in the field have different jobs, subsets of a type of immune cell that polices the barriers of the body can promote unique and opposite immune responses against the same type of infection.

22 Jul 2011

IMM researcher wins prestigious Early Career Bayer Hemophilia Award

Vanessa Oliveira, researcher at the Instituto de Medicina Molecular in Portugal won a prestigious and competitive Early Career Bayer Hemophilia Award. Oliveira will develop a strategy to reprogramme the immune system of hemophilia patients to avoid immune targeting of the most used clotting therapeutics.

14 Jul 2011

ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a U.S. patent relating to a technology for the treatment of cancer for which the Company holds an exclusive, worldwide license.

22 Jun 2011

Experimental vaccine shows promise for patients with newly diagnosed brain tumors

An experimental vaccine developed by researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute targets overactive antigens in highly aggressive brain tumors and improves length of survival in newly diagnosed patients, according to new data that was presented in a poster session at the 47th Annual Meeting of the American Society of Clinical Oncology.

17 Jun 2011

Scientists identify potential target for reversing deadly blood infection sepsis

By digging a little deeper, researchers may have found a potential target for reversing the deadly blood infection sepsis.

13 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis.

6 Jun 2011

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. today announced that they have entered into a agreement to provide IMUC with access to BioWa's patented POTELLIGENT Technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.

3 Jun 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.

26 May 2011

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

ImmunoCellular Therapeutics, Ltd today announced it will be presenting new data from the Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme.

25 May 2011

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Tregs expansion can help prevent graft-versus-host disease

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

Dysregulated neuronal RNA transport may cause Fragile X-associated tremor/ataxia syndrome

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

Dendritic cells play central role in regulation of acetaminophen's toxicity

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

New details about how dendritic cells regulate fate of naive T cells

Renowned neurosurgeon to receive National Urban League's highest honor on July 30

Skin dendritic cells promote distinct and opposing antigen-specific responses

IMM researcher wins prestigious Early Career Bayer Hemophilia Award

ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

Experimental vaccine shows promise for patients with newly diagnosed brain tumors

Scientists identify potential target for reversing deadly blood infection sepsis

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in